摘要
第二代紫杉烷类药物卡巴他赛,具有较低的P-gp亲和力,可用于治疗多西他赛耐药的前列腺癌,是临床上治疗前列腺癌的二线药物。现从新药研发的角度综述卡巴他赛新型纳米剂型的发展现状。
Cabazitaxel is a second-generation taxane drug.It has a lower P-gp affinity, it can be used for the treatment of prostate cancer in which Docetaxel is ineffective, and it is a second-line drug for the clinical treatment of prostate cancer.This review aims to discuss the development status of Cabazitaxel new nano dosage forms from the perspective of new drug development.
作者
柳宇红
姜宇
郝贵周
刘善奎
LIU Yuhong;JIANG Yu;HAO Guizhou;LIU Shankui(School of Biological Science and Technology,University of Jinan,Jinan,Shandong,250022 P.R.China;Scientific Research Department of Shandong New Era Pharmaceutical Co.,Ltd.,Linyi,Shandong,273400 P.R.China)
出处
《华西药学杂志》
CAS
CSCD
2022年第5期578-586,共9页
West China Journal of Pharmaceutical Sciences
基金
山东省重大科技创新工程项目(No.2019JZZY011116)。
